PPAR-γ thiazolidinedione agonists and immunotherapy in the treatment of brain tumors

PPAR Research

Volumn , Issue , 2008, Pages

  Lichtor, Terry ^a   Spagnolo, Alessandra ^b   Glick, Roberta P ^a,b,c   Feinstein, Douglas L ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN TUMOR; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL LINE; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; GENE CONTROL; GENE EXPRESSION; GLIOMA CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIPID METABOLISM; LYMPHOCYTOTOXICITY; NATURAL KILLER CELL; NONHUMAN; REVIEW; UPREGULATION;

EID: 45249119091     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/547470     Document Type: Review

References (44)

1. Henry R. R., Thiazolidinediones Endocrinology & Metabolism Clinics of North America 1997 26 3 553 573
2. Saltiel A. R., Olefsky J. M., Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 1996 45 12 1661 1669
3. Feinstein D. L.
4. Gelman L., Fruchart J.-C., Auwerx J.
5. Na H.-K., Surh Y.-J.
6. Grommes C., Landreth G. E., Heneka M. T.
7. Kim J.-A., Park K.-S., Kim H.-I., Troglitazone activates p 21 Cip / WAF1 through the ERK pathway in HCT15 human colorectal cancer cells Cancer Letters 2002 179 2 185 195
8. Kubota T., Koshizuka K., Williamson E. A., Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Research 1998 58 15 3344 3352
9. Posch M. G.
10. Tsubouchi Y., Sano H.
11. Fujimura S., Suzumiya J., Nakamura K., Ono J., Effects of troglitazone on the growth and differentiation of hematopoietic cell lines International Journal of Oncology 1998 13 6 1263 1267
12. Demetri G. D., Fletcher C. D. M., Mueller E., Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor- γ ligand troglitazone in patients with liposarcoma Proceedings of the National Academy of Sciences of the United States of America 1999 96 7 3951 3956
13. Mueller E., Sarraf P., Tontonoz P., Terminal differentiation of human breast cancer through PPAR γ Molecular Cell 1998 1 3 465 470
14. Sarraf P., Mueller E., Jones D., Differentiation and reversal of malignant changes in colon cancer through PPAR γ Nature Medicine 1998 4 9 1046 1052
15. Palakurthi S. S., Aktas H., Grubissich L. M., Mortensen R. M., Halperin J. A., Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation Cancer Research 2001 61 16 6213 6218
16. Colca J. R.
17. Feinstein D. L.
18. Berge K.
19. Chattopadhyay N.
20. Grommes C., Landreth G. E., Schlegel U., Heneka M. T.
21. Kato M., Nagaya T., Fujieda M., Saito K., Yoshida J., Seo H., Expression of PPAR γ and its ligand-dependent growth inhibition in human brain tumor cell lines Japanese Journal of Cancer Research 2002 93 6 660 666
22. Liu D.-C., Zang C.-B., Liu H.-Y., Possinger K., Fan S.-G., Elstner E.
23. Morosetti R., Servidei T., Mirabella M., The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines International Journal of Oncology 2004 25 2 493 502
24. Pérez-Ortiz J. M., Tranque P.
25. Strakova N., Ehrmann J.
26. Strakova N.
27. Zander T., Kraus J. A., Grommes C., Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPAR γ Journal of Neurochemistry 2002 81 5 1052 1060
28. Zang C., Wächter M., Liu H., Ligands for PPAR γ and RAR cause induction of growth inhibition and apoptosis in human glioblastomas Journal of Neuro-Oncology 2003 65 2 107 118
29. Okura T.
30. Yin F.
31. Qin C., Burghardt R., Smith R., Wormke M., Stewart J., Safe S.
32. Sugimura A., Kiriyama Y., Nochi H., Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p 21 WAF 1 / CIP 1 cyclin-dependent kinase inhibitor Biochemical and Biophysical Research Communications 1999 261 3 833 837
33. Feinstein D. L.
34. Clark R. B.
35. Klotz L.
36. Coras R., Hölsken A., Seufert S., The peroxisome proliferator-activated receptor- γ agonist troglitazone inhibits transforming growth factor- β -mediated glioma cell migration and brain invasion Molecular Cancer Therapeutics 2007 6 6 1745 1754
37. Tran T.-T., Uhl M., Ma J. Y., Inhibiting TGF- β signaling restores immune surveillance in the SMA-560 glioma model Neuro-Oncology 2007 9 3 259 270
38. Lichtor T., Glick R. P., Tarlock K., Moffett S., Mouw E., Cohen E. P., Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors Cancer Gene Therapy 2002 9 5 464 469
39. Lichtor T.
40. Lichtor T., Glick R. P., Lin H., Chopra A., O-Sullivan I., Cohen E. P., Advantages of a unique DNA-based vaccine in comparison to paclitaxel in treatment of an established intracerebral breast cancer in mice Cancer Therapy 2006 4 163 170
41. Okano J., Rustgi A. K.
42. Yin X.-Y.
43. Lake R. A.
44. Spagnolo A., Glick R. P., Lin H., Cohen E. P., Feinstein D. L., Lichtor T.